SIBIONICS GS3 Continuous Glucose Monitor

SIBIONICS (Silicon Bionics) is a Chinese company focused on chronic disease management, with products for consumers and for professional markets. Its CGM was approved for marketing in China in November 2021 as the country's first glucose monitor that needs no fingerstick calibration, and it also markets an AI fundus screening system.

The GS3 is a 14-day continuous glucose sensor measuring 24.8 x 17.8 x 2.9 mm and weighing 1.5 g. Readings update every 5 minutes over Bluetooth, an NFC tap connects the app, and glucose data can be shared remotely with healthcare professionals, with AGP reports generated in the app after at least 5 days of data.

• 14-day sensor: continuous measurement with 14 days of sensor life and memory.
• Compact design: 2.9 mm thin, 1.5 g, indicated for ages 3 and older.
• Bluetooth and NFC: 5-minute updates over Bluetooth within 10 meters, NFC tap to connect.
• AGP reports: in-app reports built from at least 5 days of data.
• Logging: one-page logging of meals, insulin and workouts.
• Remote sharing: glucose readings shared with healthcare professionals, with optional alerts.

Endocrinology clinics reviewing patients' 14-day glucose profiles during follow-up visits. Pharmacy and diabetes-care chains offering CGM-based programs with remote sharing to a physician. Corporate wellness programs screening glucose patterns for at-risk employees.

A 14-day sensor wear reduces the number of sensor changes for patients under clinic follow-up. Stated accuracy is MARD 8.7% for ages 3-17 and 8.83% for adults, according to the company page. Remote sharing lets healthcare professionals review trends between visits, and AGP reports standardize the review.

Continuous glucose monitoring is moving from type 1 diabetes into broader chronic care, with clinics and hospitals using sensor data and AGP reports to manage patients between visits. Vietnam and Southeast Asia have a growing diabetes population, which supports demand for lower-cost sensors and remote glucose review by clinicians.

SIBIONICS' Chinese-language site shows a Shenzhen subsidiary named a 2026 Shenzhen Gazelle Enterprise (2026-07) and GS3 awards in 2026-09. English pages report a nearly 500 million yuan Series D in 2022-12. The official app is currently available in EU countries. Founding year not stated.